{
    "2018-04-02": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Fast Pipeline Progress Pushes ImmunoGen Above 150% in a Year",
                "features": {
                    "keywords": [
                        "Pipeline",
                        "Progress",
                        "ImmunoGen",
                        "150%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "A Look at the 4Q17 Performance of Eli Lilly’s Elanco",
                "features": {
                    "keywords": [
                        "4Q17",
                        "Performance",
                        "Eli Lilly",
                        "Elanco"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "animal health"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "How Eli Lilly’s Neuroscience Products Performed in 4Q17",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Neuroscience",
                        "Products",
                        "4Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "neuroscience"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Understanding Athenex’s Research Platforms",
                "features": {
                    "keywords": [
                        "Athenex",
                        "Research",
                        "Platforms"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "research"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Analysts’ Ratings for Athenex and Its Peers in March",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Ratings",
                        "Athenex",
                        "Peers",
                        "March"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "How Eli Lilly’s Cardiovascular Products Performed in 4Q17",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Cardiovascular",
                        "Products",
                        "4Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "cardiovascular"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}